- Home
- PAYO vs IBRX Comparison
PAYO vs IBRX Comparison
Compare PAYO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- IBRX
- Stock Information
- Founded
- PAYO 2005
- IBRX 2014
- Country
- PAYO United States
- IBRX United States
- Employees
- PAYO N/A
- IBRX N/A
- Industry
- PAYO EDP Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYO Technology
- IBRX Health Care
- Exchange
- PAYO Nasdaq
- IBRX Nasdaq
- Market Cap
- PAYO 2.2B
- IBRX 2.4B
- IPO Year
- PAYO N/A
- IBRX N/A
- Fundamental
- Price
- PAYO $6.81
- IBRX $2.66
- Analyst Decision
- PAYO Strong Buy
- IBRX Strong Buy
- Analyst Count
- PAYO 8
- IBRX 5
- Target Price
- PAYO $10.44
- IBRX $11.40
- AVG Volume (30 Days)
- PAYO 4.4M
- IBRX 11.3M
- Earning Date
- PAYO 05-07-2025
- IBRX 05-12-2025
- Dividend Yield
- PAYO N/A
- IBRX N/A
- EPS Growth
- PAYO N/A
- IBRX N/A
- EPS
- PAYO 0.28
- IBRX N/A
- Revenue
- PAYO $996,150,000.00
- IBRX $31,222,000.00
- Revenue This Year
- PAYO $4.12
- IBRX $579.01
- Revenue Next Year
- PAYO $4.91
- IBRX $173.61
- P/E Ratio
- PAYO $24.29
- IBRX N/A
- Revenue Growth
- PAYO 14.86
- IBRX 10238.41
- 52 Week Low
- PAYO $5.03
- IBRX $1.83
- 52 Week High
- PAYO $11.29
- IBRX $7.63
- Technical
- Relative Strength Index (RSI)
- PAYO 46.54
- IBRX 53.05
- Support Level
- PAYO $6.77
- IBRX $2.43
- Resistance Level
- PAYO $6.94
- IBRX $2.79
- Average True Range (ATR)
- PAYO 0.21
- IBRX 0.23
- MACD
- PAYO -0.02
- IBRX 0.02
- Stochastic Oscillator
- PAYO 12.30
- IBRX 53.80
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.